| Prev Close | 94.88 |
| Day Low/High | 95.00 / 97.28 |
| 52 Wk Low/High | 64.72 / 126.98 |
| Avg Volume | 653.00K |
Latest News
Neurocrine Biosciences Announces FDA Acceptance Of New Drug Application For Opicapone As An Adjunctive Treatment For Patients With Parkinson's Disease
- FDA Accepts New Drug Application for Opicapone, a Once-Daily, Oral, Catechol-O-Methyltransferase (COMT) Inhibitor, as Adjunctive Therapy to Levodopa/Carbidopa
Neurocrine Biosciences Announces Conference Call And Webcast Of Second Quarter 2019 Financial Results
Conference Call and Webcast Scheduled for Monday, July 29
Neurocrine Biosciences To Present Data On INGREZZA® (valbenazine) And Opicapone At The 2019 World Congress On Parkinson's Disease And Related Disorders
- INGREZZA Data from Long-Term Phase III Studies Support Sustained Clinical Benefit, Safety and Tolerability in Patients with Tardive Dyskinesia
Neurocrine Biosciences To Present At Goldman Sachs 40th Annual Global Healthcare Conference
Live Audio Webcast will be on June 11, 2019
Neurocrine Biosciences To Present At Jefferies 2019 Global Healthcare Conference
Live Audio Webcast will be on June 6, 2019
Neurocrine Biosciences Presents New Data From RE-KINECT, The Largest Real-World Screening Study Of Possible Tardive Dyskinesia, Demonstrating The Effect Of Involuntary Movements On Patient Quality Of Life
- Nearly 30% of Patients with Possible Tardive Dyskinesia Reported Moderate-to-Extreme Problems Performing Their Usual Activities, Including Work, Housework and Leisure Activities
Neurocrine Biosciences To Present New Quality-of-Life Data Analysis From RE-KINECT, The Largest Real-World Screening Study Of Possible Tardive Dyskinesia Patients, At The 2019 American Psychiatric Association Annual Meeting
- RE-KINECT Analysis Provides Insight into the Impact of Possible Tardive Dyskinesia on Patient Health-Related Quality of Life
Neurocrine Biosciences To Present At Bank Of America Merrill Lynch Health Care Conference 2019
Live Audio Webcast will be on May 14, 2019
Neurocrine Biosciences Honors Mental Health Month And Raises Awareness Of Tardive Dyskinesia And Its Impact On Patients
- Mental Health Advocacy Community Recognizes and 25 States Declare Tardive Dyskinesia Awareness Week as Part of Mental Health Month to Raise Prominence of Tardive Dyskinesia and Highlight the Impact on the Lives of Patients
Neurocrine Biosciences And Voyager Therapeutics Announce Phase I Results For VY-AADC In Patients With Parkinson's Disease At The American Academy Of Neurology Annual Meeting
- Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson's Disease
Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating That Opicapone Added To Levodopa Resulted In A Significant And Sustained Increase In ON Time Without Troublesome Dyskinesia In Parkinson's Disease Patients With Motor Fluctuations
- More than 60% of Patients Treated with Once-Daily Opicapone 50 mg Experienced an Increase in Total ON Time of One Hour or Longer
Neurocrine Biosciences To Present Data Analyses On INGREZZA® (valbenazine) And Opicapone At The 2019 American Academy Of Neurology Annual Meeting
- Long-Term Data from Two Phase III Trials Show INGREZZA Sustained Improvement in Tardive Dyskinesia Symptoms in Patients Taking Concomitant Medications for Psychiatric Disorders
Neurocrine Biosciences Reports First Quarter 2019 Financial Results
INGREZZA® (valbenazine) First Quarter Net Product Sales of $136.4 Million with Approximately 24,200 TRx
Neurocrine Biosciences Announces Conference Call And Webcast Of First Quarter 2019 Financial Results
Conference Call and Webcast Scheduled for Monday, April 29
Neurocrine Biosciences Reports Positive Interim Results From Phase II Study Of NBI-74788 In Adults With Classic Congenital Adrenal Hyperplasia
- NBI-74788 Achieved Study Goals and Demonstrated Reductions in Key Disease Biomarkers Exceeding Predetermined Threshold for Proof-of-Concept
Neurocrine Biosciences To Present At Upcoming Healthcare Conferences
SAN DIEGO, March 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the following investor...
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AJRD, BXP, CARB, CDR, DOC, FTAI, GHDX, GOV, HOME, IKNX, LOCO, NBIX, NYLD.A, RFP, UEIC Downgrades: APU, HY, MFNC, SGMS, TFX Initiations: EEX, SSTI Read on to get TheStreet Quant Ratings' detailed report:
3 'Strong Buy' Healthcare Stocks Poised to Surge
Here are the top healthcare bets ticking all the boxes for analysts.
5 Stocks That Are Screaming Buys Right Now
Stay active and selective: These are the five best stocks to invest in right now
Spring Cleaning: Let's Tidy Up Some Trades
Not every trade can be a winner, so let's lighten the load here.
A Bullish Play on Neurocrine Biosciences
Analysts weren't shy to defend the company after Tuesday's earnings.
Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?
Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.
15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies
'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.
Watch These Biotechs and the FDA Calendar
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
3 Key Biotech Catalysts on the FDA Calendar
A roundup of biotech names with actions pending at the FDA in coming weeks.
Who Benefits From Tax Reform?
Technology and biotech companies seem to be among the big winners.
Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.
10 Sectors That Will Profit Big-Time From Oil's Crash
Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...
